Verastem, Inc. (VSTM)
Stock Price:
$1.28 USD
-0.03 (-2.29%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $1.29 +0.01 (0.78%) Oct 19, 5:25 PM
Key Info
| Market Cap |
217.00M |
| Revenue (ttm) |
22.01M |
| Net Income (ttm) |
-129.91M |
| Shares Out |
169.53M |
| EPS (ttm) |
-1.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$1.28 |
| Previous Close |
$1.31 |
| Change ($) |
-0.03 |
| Change (%) |
-2.29% |
| Day's Open |
1.32 |
| Day's Range |
1.27 - 1.33 |
| Day's Volume |
1,164,161 |
| 52-Week Range |
0.83 - 4.67 |
More Stats
| Market Cap |
217.00M |
| Enterprise Value |
115.77M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
169.53M |
| Float |
159.80M |
| EPS (basic) |
-1.41 |
| EPS (diluted) |
-1.23 |
| FCF / Share |
-0.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.07M |
| Short Ratio |
2.85 |
| Short % of Float |
6.30% |
| Beta |
0.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.86 |
| PB Ratio |
1.94 |
| Revenue |
22.01M |
| Operating Income |
-108.33M |
| Net Income |
-129.91M |
| Free Cash Flow |
-121.65M |
| Net Cash |
101.24M |
| Net Cash / Share |
0.60 |
| Gross Margin |
73.68% |
| Operating Margin |
-492.17% |
| Profit Margin |
-590.20% |
| FCF Margin |
-552.69% |
| ROA |
-31.54% |
| ROE |
-158.74% |
| ROIC |
-106.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.00*
(212.50% upside)
Low
3.00
Current: $1.28
High
5.00
Target: 4.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 17.46 | 26.72 | - | - | - | - | - | - | - |
| Revenue Growth | -34.67% | - | - | - | - | - | - | - | - |
| Gross Profit | 14.65 | 26.13 | - | - | - | - | - | - | - |
| Operating Income | -132 | -94.78 | -67.80 | -37.00 | -58.20 | -53.61 | -41.40 | -32.23 | -13.70 |
| Net Income | -149 | -72.43 | -67.80 | -36.44 | -57.87 | -53.37 | -41.20 | -31.98 | -13.68 |
| Shares Outstanding | 74.58 | 64.96 | 38.42 | 36.99 | 35.93 | 25.80 | 22.68 | 18.77 | 1.30 |
| Earnings Per Share | -2.00 | -1.37 | -1.76 | -0.99 | -1.61 | -2.07 | -1.82 | -1.70 | -10.59 |
| Operating Cash Flow | -139 | -74.52 | -57.31 | -29.48 | -45.56 | -36.90 | -26.31 | -22.60 | -9.37 |
| Capital Expenditures | -0.01 | -23.43 | - | -0.04 | -0.21 | -2.43 | -0.06 | -0.31 | -0.79 |
| Free Cash Flow | -139 | -97.94 | -57.31 | -29.52 | -45.77 | -39.33 | -26.36 | -22.91 | -10.16 |
| Cash & Equivalents | 111 | 250 | 86.67 | 81.06 | 110 | 92.88 | 101 | 56.66 | 47.90 |
| Total Debt | 108 | 120 | 14.83 | - | - | - | - | - | - |
| Net Cash / Debt | 3.72 | 129 | 71.84 | 81.06 | 110 | 92.88 | 101 | 56.66 | 47.90 |
| Assets | 145 | 277 | 89.79 | 83.63 | 113 | 98.65 | 125 | 92.92 | 59.04 |
| Liabilities | 138 | 153 | 32.11 | 11.33 | 10.63 | 9.88 | 7.82 | 2.46 | 71.80 |
| Book Value | 7.17 | 124 | 57.68 | 72.30 | 102 | 88.77 | 117 | 90.47 | -12.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Verastem, Inc. |
| Country |
United States |
| Employees |
135 |
| CEO |
Brian M. Stuglik |
Stock Information
| Ticker Symbol |
VSTM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VSTM |
| IPO Date |
January 27, 2012 |
Description
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Company and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.